Dan Lehmann

1.6k total citations
36 papers, 1.2k citations indexed

About

Dan Lehmann is a scholar working on Immunology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dan Lehmann has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 8 papers in Pathology and Forensic Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dan Lehmann's work include T-cell and B-cell Immunology (9 papers), Immune Cell Function and Interaction (8 papers) and Immunotherapy and Immune Responses (8 papers). Dan Lehmann is often cited by papers focused on T-cell and B-cell Immunology (9 papers), Immune Cell Function and Interaction (8 papers) and Immunotherapy and Immune Responses (8 papers). Dan Lehmann collaborates with scholars based in Israel, Switzerland and United States. Dan Lehmann's co-authors include Avraham Ben‐Nun, Oded Abramsky, Dimitrios Karussis, R Mizrachi-Koll, S Slavin, Haim Ovadia, Urania Vourka-Karussis, Terje Kalland, Jef C.M. Raus and Elisabeth Tournier‐Lasserve and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Immunology.

In The Last Decade

Dan Lehmann

35 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dan Lehmann Israel 19 598 351 169 158 151 36 1.2k
M. Pette Germany 14 755 1.3× 368 1.0× 206 1.2× 76 0.5× 171 1.1× 28 1.3k
Ingrid E. Gienapp United States 19 1.0k 1.7× 244 0.7× 208 1.2× 164 1.0× 170 1.1× 31 1.5k
Elise H. Tran Canada 7 1.5k 2.4× 266 0.8× 198 1.2× 124 0.8× 414 2.7× 8 1.9k
Gerhard Giegerich Germany 17 806 1.3× 280 0.8× 484 2.9× 85 0.5× 185 1.2× 29 1.6k
Elizabeth G. Lingenheld United States 19 1.2k 2.0× 183 0.5× 238 1.4× 83 0.5× 230 1.5× 25 1.6k
Thaddeus Carlson United States 11 1.0k 1.8× 276 0.8× 285 1.7× 70 0.4× 286 1.9× 12 1.6k
Hirofumi Ochi Japan 24 649 1.1× 654 1.9× 323 1.9× 137 0.9× 194 1.3× 89 1.8k
Takayuki Kondo Japan 19 1.7k 2.8× 533 1.5× 422 2.5× 136 0.9× 277 1.8× 41 2.4k
Michael J. Dauphinée United States 20 1.1k 1.9× 120 0.3× 268 1.6× 212 1.3× 214 1.4× 52 1.9k
Stephen D. Schibeci Australia 24 569 1.0× 268 0.8× 360 2.1× 68 0.4× 215 1.4× 44 1.3k

Countries citing papers authored by Dan Lehmann

Since Specialization
Citations

This map shows the geographic impact of Dan Lehmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Lehmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Lehmann more than expected).

Fields of papers citing papers by Dan Lehmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Lehmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Lehmann. The network helps show where Dan Lehmann may publish in the future.

Co-authorship network of co-authors of Dan Lehmann

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Lehmann. A scholar is included among the top collaborators of Dan Lehmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Lehmann. Dan Lehmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yehuda, Y., et al.. (2017). Genome-wide Determination of Mammalian Replication Timing by DNA Content Measurement. Journal of Visualized Experiments. 5 indexed citations
2.
Lehmann, Dan, et al.. (2004). Characterization of BoHV-1 gE envelope glycoprotein mimotopes obtained by phage display. Veterinary Microbiology. 104(1-2). 1–17. 11 indexed citations
3.
Ulrich, S., Brian C. Baumann, Robert Christian Wolf, et al.. (2003). Therapeutic drug monitoring of clozapine and relapse a retrospective study of routine clinical data. International Journal of Clinical Pharmacology and Therapeutics. 41(1). 3–13. 54 indexed citations
4.
Lehmann, Dan, et al.. (2002). Improvement of serological discrimination between herpesvirus-infected animals and animals vaccinated with marker vaccines. Veterinary Microbiology. 86(1-2). 59–68. 14 indexed citations
5.
Lehmann, Dan, et al.. (1997). Inhibition of the Progression of Multiple Sclerosis by Linomide Is Associated with Upregulation of CD4+/CD45RA+Cells and Downregulation of CD4+/CD45RO+Cells. Clinical Immunology and Immunopathology. 85(2). 202–209. 13 indexed citations
6.
Lehmann, Dan, R Mizrachi-Koll, Haim Ovadia, et al.. (1997). Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 74(1-2). 102–110. 33 indexed citations
8.
Karussis, Dimitrios, Zeev Meiner, Dan Lehmann, et al.. (1996). Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide. Neurology. 47(2). 341–346. 94 indexed citations
9.
Lehmann, Dan, et al.. (1994). Oral administration of the oxidant-scavenger N- inhibits acute experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 50(1). 35–42. 42 indexed citations
10.
Lehmann, Dan, Talma Brenner, Itzhak Wirguin, et al.. (1994). Immunomodulation of experimental autoimmune myasthenia gravis with linomide. Journal of Neuroimmunology. 55(2). 187–193. 36 indexed citations
13.
Karussis, Dimitrios, Urania Vourka-Karussis, Dan Lehmann, et al.. (1993). Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.. Journal of Clinical Investigation. 92(2). 765–772. 88 indexed citations
14.
Karussis, Dimitrios, Dan Lehmann, S Slavin, et al.. (1993). Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Annals of Neurology. 34(5). 654–660. 80 indexed citations
17.
Karussis, Dimitrios, S Slavin, Dan Lehmann, et al.. (1992). Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. The Journal of Immunology. 148(6). 1693–1698. 75 indexed citations
18.
Lehmann, Dan & Avraham Ben‐Nun. (1992). Intraperitoneal Injection of CD4+ T Cells Induces CD5 B Cells. Annals of the New York Academy of Sciences. 651(1). 579–580. 2 indexed citations
19.
Karussis, Dimitrios, S Slavin, Avraham Ben‐Nun, et al.. (1992). Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. Journal of Neuroimmunology. 39(3). 201–210. 47 indexed citations
20.
Lehmann, Dan, et al.. (1988). Androgens inhibit proliferation of human peripheral blood lymphocytes in vitro. Clinical Immunology and Immunopathology. 46(1). 122–128. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026